Calculateur numérique du modèle de Lille original au jour 7

État

clinical-review-pending

Version de la méthode

Louvet 2007 original day-7 PT-based Lille-model arithmetic v1: bilirubin evolution (µmol/L) = day-0 total bilirubin − treatment-day-7 total bilirubin; R = 3.19 − 0.101 × age (years) + 0.147 × day-0 albumin (g/L) + 0.0165 × bilirubin evolution (µmol/L) − 0.206 × renal-insufficiency indicator − 0.0065 × day-0 total bilirubin (µmol/L) − 0.0096 × day-0 prothrombin time (seconds); Lille model value = exp(−R) / [1 + exp(−R)] = 1 / [1 + exp(R)]. Renal insufficiency is 1 when day-0 serum creatinine is >1.3 mg/dL or an explicitly measured day-0 creatinine clearance is <40 mL/min, otherwise 0; 1.3 mg/dL is canonical and the source's 115 µmol/L label is approximate. Albumin accepts g/L or g/dL and normalizes to g/L; total bilirubin accepts µmol/L or mg/dL using 1 mg/dL = 17.1 µmol/L; serum creatinine accepts mg/dL or µmol/L using 1 mg/dL = (10,000 / 113.1179) µmol/L. Raw continuous unrounded 0–1 model value only; the separately printed INR equation and later day-4 variants are excluded.

Population

Adults for whom applicability of the original Louvet 2007 biopsy-confirmed severe alcohol-associated-hepatitis source context is independently established. The model was developed in 320 patients prospectively treated with corticosteroids and prospectively validated in an independent cohort of 118. Systemic corticosteroids must have been independently prescribed and actually administered for this episode; age and day-0 albumin, total bilirubin, serum creatinine, optional explicitly measured creatinine clearance, and prothrombin time in seconds must be anchored to treatment start; follow-up total bilirubin must be from exact treatment day 7; albumin must precede albumin infusion; and all analyte, specimen, assay, unit, source-value, and timing identities must be verified. This arithmetic does not diagnose alcohol-associated hepatitis, establish severity, decide corticosteroid eligibility, or direct treatment.

Limites et exclusions

The source paper's published cutoff, responder or nonresponder label, result or risk category, individual mortality or survival estimate, prognostic classification or statement, diagnosis or confirmation, corticosteroid eligibility, continuation or stopping decision, alternative-therapy selection, management, treatment, recommendation, or any other clinical decision. · Use outside the original biopsy-confirmed severe alcohol-associated-hepatitis cohorts prospectively treated with corticosteroids without independently established applicability; pediatric use; or extrapolation to another liver disease, treatment context, population, endpoint, or laboratory workflow. · Corticosteroids not actually administered; uncertain treatment start; a follow-up bilirubin from hospital day 7, day 4, or another interval; albumin obtained after albumin infusion; mismatched episodes or time points; missing, inferred, imputed, default-normal, carried-forward, censored, or nonquantitative inputs; or a partial model value. · Substitution of INR or PT ratio for day-0 PT seconds; substitution of eGFR or an estimated clearance for an explicitly measured creatinine clearance; treating the source's approximate 115 µmol/L creatinine label as the canonical exact threshold instead of >1.3 mg/dL; or unverified analyte, specimen, assay, unit, source-value, or timing identities. · The separately printed INR equation, a later day-4 model, altered coefficients or variable definitions, intermediate rounding, clamping, or implementation of any published cutoff or category.

• https://pubmed.ncbi.nlm.nih.gov/17518367/
• https://doi.org/10.1002/hep.21607

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source

PharmaTek · MDose

Version importée

4b66536936ed

État de publication

Révision clinique en cours